Hosted on MSN2h
Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
Vertex Pharmaceuticals EVP sells shares worth $1.58 million
Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing, Biller ...
Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...